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Background: Phenylketonuria is a well-known disease, yet the characteristics of the affected 
population and their use of healthcare resources have not been comprehensively evaluated. Patient 
characteristics and use of resources are subjects of interest for most governments, especially for a 
disease included in new born screening programs.  
Objective: The aim of this study was to determine characteristics and use of healthcare resources of 
patients with phenylketonuria in the region of Catalonia.  
Methods: Records of 289 patients admitted with phenylketonuria between 2007 and 2017 were 
extracted from the PADRIS database that includes admission data from primary care centers, 
hospitals (inpatient and outpatient care), extended care facilities and mental health centers.  
Results: Patient population was composed by 140 males and 149 females, and 102 patients were 
registered via newborn screening during the study period. Patients were admitted on average 2.19 
times per year, mostly into primary care centers which concentrated the biggest portion of direct 
medical expenses. Similar percentages of urgent and scheduled admissions were registered both in 
primary care and hospitals. Annual direct medical cost of treating patients with PKU was €667 per 
patient.  Finally, 66.80% of the patients suffered from chronic conditions affecting 2 or more systems, 
likely to correspond to a wide variety of conditions.  
Conclusions: Altogether, phenylketonuria patient demographics and direct medical costs in 
Catalonia have been revised. Patients diagnosed with phenylketonuria appeared 1.3 times more likely 
to suffer from chronic conditions in distinct organ systems, which is expected to have an effect on 
their use of healthcare resources. These results support the need to adapt and improve the health care 
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Phenylketonuria (PKU) is a genetic condition in which the enzyme that processes 
phenylalanine, phenylalanine hydroxylase (PAH), is deficient or absent. As a consequence, 
phenylalanine accumulates in the blood, causing a series of symptoms that vary in accordance 
with age of diagnosis and underlying genetic heterogeneity. Once hyperphenylalaninemia 
(HPA) is detected, the patient is tested for PAH deficiency and to exclude a non-
phenylketonuric HPA caused by the deficiency of its cofactor, tetrahydrobiopterin (BH4) [1].  
When PKU is properly diagnosed the first days of life, patients benefit from nutritional, 
clinical and biochemical follow-up, and few symptoms are observed; contrarily, when 
undiagnosed, symptoms include eczema, seizures, autism, behavioral issues, and eventually, 
severe intellectual disability [2]. Disease prevalence varies among geographical regions. In 
Europe, it affects one per 10,000 live births [3], although in Turkey it increases to one in 
4,000 [4]. On the contrary, in Finland, prevalence is as low as one per 100,000 live births [5]. 
In Spain, the geographical distribution of the underlying mutations causing PKU has been 
analyzed, revealing differences between Mediterranean descendants and originals from the 
north-west of the country [6].  
PKU is currently diagnosed the first days of life due to the well-established new born blood 
screening.  Such screenings were established in Spain in 1978 (Real Decreto 2176/1978, 25th 
of August) and were soon implemented in the whole country [7]. Their benefits have been 
evident, with practically all symptoms of the disease being reduced only by dietary restriction 
[8]. Phenylalanine-restricted diets are still the primary treatment for PKU, often in 
combination with sapropterin, which reduces blood phenylalanine, or enzyme substitution 
therapy [9]. In general terms, PKU is a well-known disease, yet the characteristics of the 
affected population and possible regional discrepancies have not been comprehensively 
5 
 
evaluated. Similarly, patients’ use of healthcare resources in a certain region is a subject of 
interest for most governments, especially for diseases part of new born screening programs. 
In such cases, neonatal screenings are justified based on the reduction of costs associated 
with treating patients later on [10]. A previous study analyzed the costs associated to PKU in 
Spain, together with its epidemiology [11]; however, in Spanish regions as Catalonia (7.5 
million inhabitants) the regional government is in charge of the health care system, hence the 
interest of regional evaluations. In order to facilitate the management and examination of 
patient data, the local government has developed a specialized program that recruits patient 
information: the data analysis for research and innovation in health program (PADRIS) [12]. 
With this in mind this study was designed to evaluate the current status of PKU in the region 
of Catalonia, focusing on analyzing patient characteristics, revising disease management and 
calculating the direct medical costs of the disease. 
MATERIALS AND METHODS 
Records of all registered patients with a diagnosis of PKU in the region of Catalonia (7.5 
million inhabitants) between 2007 and 2017 were analyzed. Data was obtained from project 
PADRIS via the approval from the University of Barcelona's Bioethics Commission. 
Parameters such as health centers and medical history identifiers were re-coded prior to 
extraction to maintain records anonymized in accordance with the principles of Good Clinical 
Practice and the Declaration of Helsinki. 
The database includes detailed information on patients’ use of healthcare resources, 
comprising primary care centers, hospitals (inpatient and outpatient care), emergency rooms 
(ER), extended care facilities and mental health centers. Records in the database are validated 
automatically via the evaluation of data consistency. Patient diagnoses and procedures were 
determined by means of the 9th revision of the International Statistical Classification of 
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Diseases and Related Health Problems (ICD-9). When necessary, the extraction of single-
patient information was carried out by eliminating repeated records corresponding to 
separated admissions, relying on the first admission registered during the study period as the 
index event. 
The classification assigns patients an adjusted morbidity group (GMA), according to the 
number of systems they have affected by chronic diseases, and into 5 levels of complexity or 
risk. As it increases, GMA level correlates with a higher number of healthcare admissions of 
these patients and major pharmaceutical costs [13]. Direct medical costs associated with the 
use of healthcare resources were calculated based on the mean costs of medical procedures 
determined by the Catalan government for the year 2013 [14, 15]. 
Data presentation is mainly descriptive. Statistical analyses were performed using Microsoft 
Excel© Professional Plus 2010 (Microsoft Corporation, Redmond, WA, USA). 
RESULTS 
The study evaluated records of 289 patients diagnosed with PKU in the region of Catalonia 
between 2007 and 2017 (Table 1). Not significant differences were observed in the 
percentage of male and female patients, 48.44% vs. 51.56%. Surprisingly, patients’ mean age 
at first admission was 14.90 years (SD=18.07), although age median was of 8 years. In total, 
102 patients included in the study were registered after diagnosis via newborn screening.  
A total number of 15,018 healthcare admissions were analyzed, corresponding to primary 
health centers, hospitals, ER, extended care facilities and mental health consultations. Data 
was gathered between the years 2007 and 2017, averaging 2.19 annual admissions per 
patient. Significantly, 8.78 admissions were registered annually in primary care centers and 
only 0.23 annual admissions per patient  were into hospitals.  
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All available information was used to determine the origin of admissions in primary care and 
hospitals, and the nature of emergency admissions (Figure 1). A similar proportion of 
scheduled and urgent visits were observed both in hospitals and primary care, while 
admissions into ER were mainly due to minor conditions with no vital risk associated. 
Mean hospitalization time was 4.57 days, while the mean time patients spent in extended care 
facilities was 9.8 days. Generally, admissions into ER required stays of less than a day. After 
hospital discharge, 95.03% of the patients returned to their residence, a percentage slightly 
lower, 89.73%, in ER admissions (Table 2).  
Patient admission files include a principal diagnosis (hospitalization motive), which was 
PKU in all cases, and a series of secondary diagnoses registered during the hospitalization. 
Secondary conditions diagnosed in more than 1.5% of admissions were acute nasopharyngitis 
(4.40%), unspecified essential hypertension (4.06%), asthma (3.41%), diabetes mellitus type 
II (2.59%), diabetes mellitus type I (1.94%) and acute tonsillitis (1.58%) (Table 3).  
The Catalan institute of health (ICS) assigns patients a value according to the number of 
systems they have affected by chronic conditions. The year 2016 (last available data), 49.80% 
of patients with PKU had 2 or 3 systems affected by a chronic condition, and 17.00% of 
patients had 4 or more systems affected (Figure 2). A 5.13% and 2.66% increase was 
observed in each of these two categories since 2014. Two distinct approaches have been used 
to approximate the costs that PKU patients represent for the health care system.  In terms of 
disease complexity or risk associated with patients’ condition, in 2016 there were 7 times 
more patients in this group at very high risk, and 67% of patients displayed a certain level of 
risk versus the 50% in the general population (Figure 3). This data suggests that increased 
medical costs will derive from the treatment of patients with PKU in comparison with the 
general population.  
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On the other hand, an approximation to the direct medical costs of treating patients with PKU 
was made based on the mean costs of medical procedures established by the regional 
government (Table 4). Resources destined to primary healthcare were estimated based on the 
mean cost per admission according to its urgency. Thus, primary attention costs were the 
most relevant, summing €641,134. ER costs were calculated equally. Hospitalization costs 
were estimated per admission in outpatient consultations, and based on the average days of 
stay (1 day or more) and the cost per day. Finally, resources associated to stays in extended 
care facilities were determined by the cost per admission. Altogether, the annual direct 
medical cost per patient equaled €667, a total amount that reflects the cost to treat a patient 
with PKU 
Finally, patients’ contribution to pharmaceutical expenses was considered of significance to 
infer medical costs. Patients are assigned a co-payment percentage according to income, age 
and disease. The majority of patients, 54.21%, contributed to 40% of pharmaceutical 
expenses (Table 5). 8.30% of patients were exempted from contribution due to age or long 
term unemployment. 
DISCUSSION 
The present study revised all admission records of patients registered with PKU between 
2007 and 2017 in the region of Catalonia. Altogether, results showed a predominance of 
admissions into primary care centers versus secondary care, with an annual cost per patient 
of €667. A significant frequency of multimorbidities was also measured among these 
patients. 
The analysis revealed few differences to previous evaluations in the whole country. Patients’ 
age at first admission, 14.90 years, was relatively elevated in comparison with the 4.5 years 
determined in Spain [11]. However, patients’ diagnoses are registered in the database solely 
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after 2007, and diagnoses made before that year are not included. Thus, patients born and 
diagnosed before the study period elevate this parameter preventing a correlation with PKU’s 
first diagnosis age.   
Patients were admitted on average 2.19 times per year into a healthcare center, mostly into 
primary care centers. The Spanish healthcare system, as many others, promotes the use of 
primary care as a method to increase prevention and maximize healthcare resources [16].  In 
addition, the characteristics of PKU and its relatively simple control through diet, determine 
a need for general attention received in primary care facilities, and a minority need for urgent 
attention [2], consistent with the results of this study.  
In terms of secondary diagnoses and comorbidities, no clear tendencies have been identified. 
A number of patients suffer from chronic conditions as diabetes type I and II, hypertension 
or asthma, but GMA indicators reflect much higher percentages; 66.8% of the patients had 
chronic conditions affecting 2 or more systems in 2016, while in the general population this 
percentage was 51.7 the same year [17]. The low percentages obtained in the analysis of 
secondary diagnoses in admission data suggest that patients’ comorbid conditions correspond 
to a great variety of diseases. This data supports the findings of previous studies that 
described an elevated presence of multimorbidities in PKU patients affecting various organ 
systems, including conditions as allergic and chronic rhinitis, esophageal disorders, 
overweight, anemia, gastroesophageal reflux disease, dermatitis and eczema, all significantly 
higher than matched non-PKU controls [18]. Therein, it is speculated that HPA could have 
consequences beyond neurologic, neurocognitive and neuropsychiatric conditions, but 
further research is required to evaluate that option. Equally, the restrictive diet necessary to 
control PKU could have consequences in other organ systems as differences in parameters 
as fat oxidation have been confirmed [19].  
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On the other hand, the typical neurologic manifestations of an untreated PKU [20] were not 
detected in this study; the low prevalence of these conditions indicated that the elevated age 
of first admission does not reflect age of diagnosis in the region  
In general terms, multimorbidity groups have been associated with an increased complexity 
of disease management and, subsequently, increased medical costs [21]. Additionally, in 
Catalonia, the ICS has determined a correlation between the presence of multimorbidities 
and an increased risk and subsequent use of healthcare resources [13]. Health systems are 
rarely prepared to handle multimorbidity [22], hence the interest of governments in 
evaluating disease costs and their relation with multimorbid patients. 
The direct medical costs of PKU patients summed €1,348,364 between 2007 and 2017, with 
a mean annual cost per patient of €667. This cost is presumed higher than in the general 
population as a consequence of the major use of healthcare resources that derives from the 
higher portion of patients with chronic comorbid conditions. In Spain cost estimations 
situated annual costs of PKU at around €4,239 in 2015, however, therein, calculation methods 
were based on patients’ diagnoses and are not entirely comparable [11]. Currently, the 
majority of costs associated with the disease are indirect costs, covered by families and 
patients, due to the extended use of a dietary treatment [23, 24], although prospective 
treatments facing all disease outcomes might increase medical costs [25], dramatically rising 
as well by the presence of comorbid conditions. 
Finally, a number of limitations could have influenced the results of this study. Data 
recording in the distinct healthcare sources did not begin uniformly in 2007, and no previous 
information is available for patients born before that year. Moreover, patients with PKU may 
not need medical attention in relation with the illness for several years, and a number of 




The characteristics and use of healthcare resources of patients with PKU in the region of 
Catalonia have been revised. The increased presence of multimorbid conditions affecting 
distinct organ systems supports the need to evaluate the weight of secondary symptoms 
derived from this illness. Further research will be required to determine the importance of 
multimorbid conditions in healthcare use patterns, which will be essential in order to adapt 
and improve health care systems. 
 
TRANSPARENCY  
Declaration of funding 
This research did not receive any specific grant from funding agencies in the public, 




Not applicable.   
Competing interests 
The author declares no competing interests. 
Ethics approval and consent to participate 
Project approved by the University of Barcelona's Bioethics Commission. Patient consent 
was not required for this study.  
Data sharing statement  
Deidentified individual participant data will not be made available due to legal stipulations 




LIST OF ABBREVIATIONS 
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TABLES 
Table 1 Description of the studied population based on index event (first admission). 




Number of patients  289 
    % of male patients 48.44 
    % of female patients 51.56 
Patients’ age (years)  
    Mean ± SD 14.90 ± 18.07 
    Median  8 






Table 2 Patients’ destination after discharge from hospitals and ER (=Emergency 
Room). 
 
 Hospitals ER 
Patients’ residence 95.03% 89.73% 
Admission for inpatient care - 5.50% 
Discharge, external care 1.86% 0.00% 
Transfer to a extended care facility  0.93% 4.78% 









Diagnoses % of cases 
Acute nasopharyngitis; Coryza 4.40 
Unspecified essential hypertension 4.06 
Asthma   3.41 
Diabetes Mellitus type II 2.59 
Diabetes Mellitus type I 1.94 
Acute tonsillitis  1.58 
 
 
Table 4 Direct medical costs  (2007-2017) based on mean costs of medical procedures 
established by the regional government. ER=Emergency Room. 
 Admissions     Total cost 
  Scheduled Cost Urgent Cost  















    




    




    
ER 882 € 130    € 114,660 
Total       € 1,348,364 
 
 




Patients’ contribution % of patients 
10% contribution  (monthly limit at € 8.23)  11.07 
10% contribution  (monthly limit at € 18.52) 0.35 
40% contribution 51.21 
50% contribution 27.34 
60% contribution 0.35 
60% contribution (monthly limit at €61.75) 0.35 
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Figure 1 Origin of admissions of phenylketonuria patients. 
Figure 2 Comorbidities in patients with phenylketonuria. 
Figure 3 Disease complexity levels associated to risk (1 -green- low risk to 5 -red- very 
high risk) in A) general population [13] and B) patients with phenylketonuria in 2016. 
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